索拉非尼治疗原发性肝癌不良反应的观察及护理

目的总结肝癌患者口服索拉非尼出现不良反应的观察及护理要点。方法回顾性分析本院2008年1月-2009年9月27例肝癌患者口服索拉非尼出现的不良反应,并总结护理经验。结果 1例晚期肝癌合并腹水患者服用索拉非尼1个月后,因全身器官功能衰竭而死亡。主要不良反应发生情况:厌食8例(29.6%),恶心5例(18.5),腹泻3例(11.1%),疲劳9例(33.3%),脱皮6例(22.2%),皮疹7例(25.9%),手足综合征8例(29.6%),口腔溃疡3例(11.1%),白细胞低下1例(3.7%),发热6例(22.2%)。结论索拉非尼作为分子靶向治疗的新药,服药期间应密切观察患者的不良反应,并及时采取相应的护理措施,使患者顺利完成治疗。

Objective To sum up the key points of nursing the adverse drug reactions caused by oral administraticn of Sorafenib in primary liver cancer patients. Methods Retrospective analysis was conducted to investigate the adverse drug reactions caused by oral administration of Sorafenib in 27 primary liver cancer patients from January 2008 to September 2009. Then the nursing experience was concluded. Results Only 1 patient developed into advanced primary liver cancer and died of multiple organ failure. The major common adverse reactions included anorexy in 8 cases （29.6%）, nausea in 5 cases （18.5%）, diarrhea in 3 cases （11.1%）, tiredness in 9 cases （33.3%）, desquamation in 6 cases （22.2%）, skin eruption in 7 cases （25.9%）, hand foot skin reaction in 8 cases （29.6%）, canker sore in 3 cases （ 11.1% ）, reduction of leucocyte in 1 case （ 3.7% ）, and fever in 6 cases （22.2%）. Condusions Sorafenib, as novel medicine for molecular targeted therapy, are susceptible to adverse reactions, which needs close observation during administration. The corresponding nursing measures are decisive for the smooth completion of treatment as well.